Roche RA Drug Actemra Wins Support of US FDA Panel
Roche is happy to announce that its rheumatoid arthritis drug Actemra (tocilizumab) has won the recommending approval of the US FDA’s Arthritis Advisory Committee.
The committee’s vote was made after Roche presented results from five Phase III clinical trials. The clinical development program evaluated the effects of Actemra on signs and symptoms of RA, physical function, progression of structural damage, and health-related quality of life.


I would like the patients to understand their condition better in order to help them discern what is best for their life with arthritis in conjunction to what their doctors are telling them! .. 
